THE TREATMENT OF STEROID-INDUCED BONE LOSS IN TRANSPLANTATION

Osteopenia after transplantation is a significant cause of morbidity. Despite the lack of randomized, placebo-controlled trials in renal tra nsplantation, there is literature supporting both the prevention and t reatment of existing corticosteroid-induced osteoporosis with antireso rptive agents, such as calcitonin and bisphosphonates. The newer pharm acologic agents, nasal spray calcitonin and alendronate, have shown pr omising results in postmenopausal osteoporosis, and their ease of admi nistration and low incidence of side effects make them ideal for renal transplant patients.